

1 **Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough**  
2 **infections**

3 Timothy Farinholt, PhD<sup>1</sup>, Harsha Doddapaneni, PhD<sup>2,3</sup>, Xiang Qin, PhD<sup>2,3</sup>, Vipin Menon, PhD<sup>2,3</sup>,  
4 Qinchang Meng, PhD<sup>2,3</sup>, Ginger Metcalf<sup>2,3</sup>, Hsu Chao, DVM<sup>2,3</sup>, Marie-Claude Gingras, PhD<sup>2,3</sup>,  
5 Paige Farinholt, MD<sup>4</sup>, Charu Agrawal, MD<sup>4</sup>, Donna M. Muzny M.Sc.<sup>2,3</sup>, Pedro A. Piedra, MD<sup>1</sup>,  
6 Richard A. Gibbs, PhD<sup>2,3</sup>, Joseph Petrosino, PhD<sup>1</sup>

7  
8 <sup>1</sup>Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology  
9 and Microbiology, Baylor College of Medicine, Houston, TX, USA <sup>2</sup>Department of Molecular and  
10 Human Genetics, Baylor College of Medicine, Houston, TX, USA <sup>3</sup>Human Genome Sequencing  
11 Center, Baylor College of Medicine, Houston, TX, USA <sup>4</sup>Department of Medicine, Baylor College  
12 of Medicine, Houston, TX, USA

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 **Key Points**

28 **Question:** Which SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one  
29 interventional monoclonal antibody treatment, and one death?

30 **Findings:** Viral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-  
31 CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may  
32 possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273,  
33 and Covaxin BBV152.

34 **Meaning:** Delta variant may pose the highest risk out of any currently circulating SARS-CoV-2  
35 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.

36

37 **Abstract**

38 **Importance:** Vaccine breakthrough by an emergent SARS-CoV-2 variant poses a great risk to  
39 global public health.

40 **Objective:** To determine the SARS-CoV-2 variant responsible for 6 cases of vaccine  
41 breakthrough.

42 **Design:** Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for  
43 SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then  
44 sequenced by Swift Normalase Amplicon Panels to determine the causal variant.

45 **Setting:** Transmission event occurred at events surrounding a wedding outside of Houston, TX.  
46 Two patients from India, likely transmitted the Delta variant to other guests.

47 **Participants:** Following a positive SARS-CoV-2 qPCR test at a third-party site, six fully  
48 vaccinated patients were investigated. Three males and three females ranged from 53 to 69  
49 years old. One patient suffered from diabetes while three others were classified as overweight.  
50 No significant other comorbidities were identified. None of the patients had a history of failed  
51 vaccination.

52

## 53 Introduction

54 High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably  
55 Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429  
56 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).  
57 Each of these strains gained advantageous mutations to become a dominant strain, e.g., Iota  
58 first discovered November 23, 2020, represented 45% of new cases as of February 7, 2021<sup>1</sup>.  
59 Increased transmissibility results from genomic changes such as nonsynonymous mutations in  
60 the receptor-binding domain (RBD) of the S-gene (encodes the spike protein) conferring higher  
61 binding affinity to host angiotensin-converting enzyme 2 (ACE2) receptors or more efficient  
62 cleavage by Transmembrane Serine Protease 2 (TMPRSS2) and subsequently, viral entry<sup>2,3</sup>.  
63 Mutations could also lead to vaccine breakthrough<sup>4</sup>. The spike protein's RBD is  
64 immunodominant<sup>5</sup>, targeted by convalescent sera and vaccine-elicited antibodies (Pfizer  
65 BNT162b2<sup>6</sup>), though evidence suggest substantial role of the amino-terminal domain (NTD).  
66 Mutations in the RBD therefore pose a risk of allowing immune evasion to one or more of the  
67 current vaccines<sup>4</sup>. The Kappa and Delta variants emerged from the Indian state of Maharashtra  
68 in December 2020, contributing to a resurgence of cases in the country, representing 70% of  
69 daily new cases on May 2, 2021<sup>7</sup>. The B.1.617 lineage is now widely circulating in over 50  
70 countries based on viral sequence data and is classified as a variant of concern by the CDC.  
71 The Kappa and Delta variant lineages are defined by 7 and 8 nonsynonymous mutations in the  
72 S protein respectively (Figure 1).  
73 Emergent data suggests partial immunity to the Kappa variant, as convalescent sera and  
74 vaccine-elicited (Pfizer BNT162b2 and Moderna mRNA-1273) antibodies show a 2.3- and 4-fold  
75 reduction in neutralization in vitro respectively (noting that this study used protein-pseudotyped  
76 lentiviruses lacking the T478K mutation found in Delta variant)<sup>8</sup>. A test negative case control  
77 study estimated the effectiveness of vaccination (two weeks post second vaccination) against

78 symptomatic disease by Delta variant to be as high as 88% for Pfizer BNT162b2 in the UK  
79 (compared to 93% for Alpha variant)<sup>9</sup>.  
80 Here we describe a transmission of a Delta variant containing SARS-CoV-2 strain, between  
81 family members associated with events surrounding a wedding with 92 attendees, near  
82 Houston, Texas. Attendance required guests be fully vaccinated and took place outdoors in a  
83 large, open-air tent. To date, 6 individuals have tested positive for SARS-CoV-2, all patients  
84 were symptomatic, one patient severely enough to receive monoclonal antibody infusion  
85 treatment (Regeneron Pharmaceuticals Inc.) and one patient has died. Encounter timings and  
86 viral sequence similarities suggest the strain containing the Delta variant was transmitted to  
87 wedding guests from two patients travelling from India. With no history of vaccine failure in  
88 these patients, our observations suggest these are true cases of vaccine breakthrough,  
89 mediated by the Delta variant.

90

## 91 **Results**

92 In early April, 2021, Patient 0a, a man with no comorbidities, and Patient 0b, a woman with  
93 diabetes, travelled from India to attend a wedding in Texas (designated 0a and 0b due to  
94 difficulty establishing true patient 0). Both tested negative for SARS-CoV-2 by qPCR as part of  
95 the pre-flight criteria. Formal wedding events were held outdoors and in a large open-air tent  
96 and attendance required full vaccination (Patient 0a and 0b travelled to Houston 10 days after  
97 their second doses of Covaxin BBV152, Table 1). Patients 1-5 confirmed having close  
98 encounters with Patient 0a and 0b at the wedding. Events were attended by fewer than 100  
99 guests.  
100 On the evening of the first night of the wedding, Patient 0b complained of fatigue but associated  
101 it with diabetes and jet lag. Patient 0a developed a cough two days after the wedding and both  
102 him and Patient 0b developed a fever three days after. Patient 0a and 0b tested positive for  
103 SARS-CoV-2 by nasal swab qPCR 4 days after the wedding at a third-party site. Patient 0a's

104 symptoms progressed over the following days and was admitted to the hospital on day 6 post  
105 wedding. He was transferred to Baylor St. Luke's hospital in the Texas Medical Center with  
106 worsening symptoms. A month after the wedding, Patient 0a died from complications of COVID-  
107 19.

108 Five other guests have tested positive for SARS-CoV-2 following confirmed interactions with  
109 Patient 0a and 0b. All positive patients received Pfizer BNT162b2, Moderna mRNA-1273, or  
110 Covaxin BBV152 (Table 1). Six of these have experienced symptoms of COVID-19 (Table 1).  
111 Patient 1, who received the Pfizer BNT162b2 vaccine developed severe symptoms and was  
112 admitted to Baylor St. Luke's hospital for monoclonal antibody infusion treatment (Regeneron  
113 Pharmaceuticals Inc.) on ten days after the wedding. The density of vaccine breakthrough  
114 resulting in COVID-19 symptoms suggested the patients were carrying a SARS-CoV-2 variant.  
115 To characterize the variant, total RNA was extracted from nasopharyngeal swabs of each of the  
116 6 patients. All positive for SARS-CoV-2 Wuhan-Hu-1 and negative for Alpha variant by qPCR  
117 (Table 1). Human RNase P (RP) gene control values suggested sampling of patients and RNA  
118 isolation were performed optimally. Amplicon libraries were successfully prepared from all 6  
119 qPCR positive samples (N1 Ct value 17 – 29), with 900,754 – 2,381,756 pass-filter reads  
120 generated using Swift Biosciences Sarscov2 analysis pipeline (sTable 1). Median sequence  
121 coverage ranged from 2085x to 12,932x with >99.7% of the genome covered at 40x or greater.  
122 All 6 samples were identified as the SARS-CoV-2 Delta variant based on the presence of the 10  
123 mutations listed by the CDC's 'Selected Characteristics of SARS-CoV-2 Variants of Interest'.  
124 These mutations, located on the S protein were T19R, (G142D), 156del, 157del, R158G,  
125 L452R, T478K, D614G, P681R, D950N. 156del, 157del, R158G are annotated as a single  
126 mutation (S:GAGTTCA22028G:Glu156\_Arg158delinsGly) due to their proximity (Figure 1).  
127 Phylogenetic analysis places each patient sample in a subclade of the Delta variant (white box,  
128 Figure 2).

129

## 130 **Discussion**

131 Ending the current SARS-CoV-2 pandemic requires limiting the spread through continued  
132 vigilance of masking, social distancing, and vaccination. Variants emerge from areas  
133 experiencing uncontrolled viral spread and display increased transmissibility due to mutations in  
134 the spike protein. These mutations may occur in the antigenic region of the RBD, altering  
135 binding sites for vaccine-elicited antibodies. Mutations such as the ones found in the Kappa  
136 variant, provide partial resistance to antibody neutralization (Pfizer BNT162b2, Moderna mRNA-  
137 1273, Regeneron<sup>8</sup>, and Covaxin BBV152<sup>10</sup>), likely due to changes in epitope sequence.  
138 Vaccine breakthrough by highly transmissible variants (Delta variant up to 50% more  
139 transmissible than Alpha variant, SAGE) could lead to significant setbacks in pandemic control  
140 efforts, requiring renewed social distancing and masking efforts. Significant vaccine  
141 breakthrough could necessitate vaccine boosters or targeted lockdowns to reduce spread of  
142 infection. An analysis of spike protein epitopes found several antigenic regions (IDa-IDi, Zhang  
143 et al.). Delta variant spike protein contains mutations in three of these regions (450–469 IDf,  
144 480–499 IDg, and 522–646 IDh, Figure 1) possibly resulting in decreased neutralization by  
145 vaccine-elicited antibodies.

146 According to the cases presented in this study, antibodies elicited in patients receiving Pfizer  
147 BNT162b2, Moderna mRNA-1273, and Covaxin BBV152 may provide decreased immunity to  
148 the Delta variant. It is possible that some individuals in this study failed to produce an effective  
149 immune response to their immunization, however, none of the patients had a history of vaccine  
150 failure.

151 Our observations support continued efforts to generate SARS-CoV-2 genomic sequences from  
152 positive patient samples, in order to identify possible vaccine breakthrough mutations. The  
153 continued effectiveness of vaccine-elicited antibodies towards SARS-CoV-2 variants highlights  
154 the importance of vaccination efforts. Partial efficacy of current vaccines (70% at 75% coverage)

155 is theoretically sufficient to stop a pandemic<sup>11</sup>. Slowing the spread could prevent emergence of  
156 future variants, hastening the end of this pandemic.

157

## 158 **Materials and Methods**

### 159 **Specimen collection and ethical considerations**

160 All individuals were initially tested by third party SARS-CoV-2 testing sites. To confirm,  
161 nasopharyngeal swabs were collected by a physician or nurse as close to the first positive test  
162 as possible. Samples were submitted to the Alkek Center for Metagenomics and Microbiome  
163 Research for RNA extraction and the Human Genome Sequencing Center for qPCR  
164 confirmation. Protocols for collection, qPCR testing, and whole genome sequencing were  
165 approved by the Baylor College of Medicine Institutional Review Board (H-47423).

166

### 167 **cDNA synthesis and amplicon libraries.**

168 RNA extracted from nasopharyngeal swabs of six individuals that tested positive for SARS-  
169 COV-2 using qPCR was converted to 1st strand cDNA using SuperScript™ IV First-Strand  
170 Synthesis System (Thermo Fisher, Cat. No. 18091050). The 1st strand cDNA reaction was  
171 performed starting with 10 µl of total RNA in 25 µl reaction mix, which was incubated at 23°C for  
172 10 minutes followed by 50°C for 50 minutes. The resulting 1<sup>st</sup> strand cDNA was then diluted with  
173 DEPC treated water, where for two samples with Ct<24 cDNA was diluted 20 times and for the  
174 remaining four samples, with Ct>24, cDNA was diluted 2 times, respectively. This diluted 1<sup>st</sup>  
175 strand cDNA (10 ul) was used as input for amplification of the SARS-CoV-2 viral genome, using  
176 the SARS-CoV-2 Additional Genome Coverage Panel (Cat#COVG1V2-96). This panel was  
177 designed against SARS-CoV-2 Wuhan-Hu-1 strain (NC\_045512.2) and has 345 amplicons of  
178 116-255 bp (average 150 bp) that cover 99.7% (29,828 of 29,903 total bases) of the genome.  
179 These amplicons come in a single tube, and the workflow involves two rounds of PCR, a  
180 multiplex PCR (4 + 18 cycles) and the indexing PCR (9 cycles) to generate sequence ready

181 libraries. The reaction mixes and the thermocycler conditions were performed according to the  
182 Swift Normalase® Amplicon Panels (SNAP) Workflow. Libraries were barcoded with 8bp unique  
183 dual indices at the Indexing PCR. For library normalization, the 2 nM Normalase I protocol was  
184 performed on libraries individually, followed by pooling 5 µl of each post-Normalase I library to  
185 perform Normalase II reaction, which results in sequence ready library pool. Before sequencing,  
186 the normalized library pool concentration was measured using qPCR with KAPA Library  
187 Quantification Kits (Roche, KK4835, 07960204001).

188

### 189 **Illumina Sequencing.**

190 The pooled SARS-CoV-2 amplicon libraries were sequenced on Illumina NovaSeq 6000 S4  
191 flowcell to generate 2x150bp reads.

192

### 193 **Swift amplicon data analysis.**

194 Swift amplicon data were analyzed using Swift Biosciences Sarscov2 analysis pipeline  
195 ([https://github.com/swiftbiosciences/sarscov2analysis\\_docker](https://github.com/swiftbiosciences/sarscov2analysis_docker)) with minimum read coverage  
196 depth of 3. The GATK variants were next filtered with allele fraction  $\geq 80$ , and min read depth  
197  $30\times^{12,13}$ . Swift analysis pipeline produced variant vcf file, consensus genome, pangolin lineage  
198 and Nextclade assignment (<https://clades.nextstrain.org/>). Variant vcf from Swift amplicon data  
199 was also annotated using SnpEff<sup>13</sup>.

200

### 201 **Phylogenetic Analysis.**

202 Sequences for the designated variants of concern and variants of interest by centers for disease  
203 control (CDC), was downloaded from GISAID on 2<sup>nd</sup> June 2021<sup>15</sup>. All samples downloaded from  
204 GISAID, were analyzed using Pangolin V3.0.3 with pangoLEARN 2021-05-27<sup>16</sup> to ensure that  
205 the variant designation assigned by GISAID is accurate. Global alignment of 334 sequences  
206 including the sequences from the current study was done using MAFFT v7.480<sup>17</sup>. Maximum-



207 likelihood phylogenetic tree with boot strap (5,000) was generated using IQ-Tree V2.1.2<sup>18,19</sup>.  
208 Annotation and visualization of the tree was carried out by using FigTree v1.4.4  
209 (<http://tree.bio.ed.ac.uk/software/figtree/>). Clades were labeled with the WHO nomenclature.

210

## 211 **Acknowledgments.**

212 Part of this work was supported by the National Institute of Allergy and Infectious Diseases  
213 (Grant#1U19AI144297). The authors are grateful to the production teams at HGSC for data  
214 generation. We also thank Swift Biosciences for their input for amplicon sequencing. We  
215 gratefully acknowledge the authors and the originating and submitting laboratories of the  
216 sequences from the GISAID hCov-19 Database on which our research was based. See  
217 supplemental acknowledgment for details.

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233 **Figure 1.** Spike protein mutation prevalence in SARS-CoV-2 variant lineages. Only mutations  
234 found in greater than 50% in at least one lineage are displayed. Green text denotes a mutation  
235 found in all patients in this report. Figure modified from Outbreak.info<sup>5</sup>

236

237 **Figure 2.** Phylogenetic analysis of SARS-CoV-2 variants. All patients (white box) cluster in a  
238 sub clade of the Delta variant (red). Sequences obtained from GISAID.

239

240 **Supplementary Figure 1.** Mutation metrics from sequencing results for all 6 samples. Figure  
241 generated using Coronapp<sup>9</sup>

Figure 1




Figure 2




Table 1. Patient demographics, vaccine history, and symptoms

Sample	Sex	Age	Height (cm)	Weight (kg)	Vaccine received	Symptoms	Comorbidities†	N1 qPCR Ct
Patient 0a	Male	67-69	177.8	81.6	Covaxin BBV152	Fever, cough, body aches, fatigue, loss of taste and/or smell, Shortness of breath at rest, Shortness of breath with activity	None	29
Patient 0b	Female	65-70	152.4	53	Covaxin BBV152	Fever, cough, body aches, fatigue, loss of taste and/or smell, Shortness of breath at rest, Shortness of breath with activity	Diabetes	27
Patient 1	Male	60-66	172	68	Pfizer BNT162b2	Cough, fatigue	None	17
Patient 2	Male	59-64	170.1	77	Pfizer BNT162b2	Fever, cough, fatigue	Hypertension	24
Patient 3	Female	51-56	155	63.5	Moderna mRNA-1273	Fever, cough, body aches, fatigue, loss of taste and/or smell	Overweight	25
Patient 4	Female	51-56	162.6	88.5	Moderna mRNA-1273	Fatigue, loss of taste and/or smell	Overweight	22

† - As defined by the Centers for Disease Control and Prevention

Supplementary table 1. Swift Amplicon Normalase Panel sequencing metrics

Sample	Reads passed					Bases without coverage						
	filter	Yield (Mb)	Mean	Stdev	Median	Maximum	0x %	>=5x %	>=10x %	>=20x %	>=40x %	
Patient 0a	900,754	272	2941.96	3405.34	2085	216863	46	0.15	99.85	99.84	99.83	99.8
Patient 0b	2,381,756	719	15470.4	11416.18	12932	108010	43	0.14	99.85	99.85	99.84	99.84
Patient 3	1,458,602	440	9711.2	8845.54	7534	81585	42	0.14	99.83	99.81	99.8	99.72
Patient 1	1,424,114	430	8651.92	14635.48	4457	159997	40	0.13	99.84	99.84	99.83	99.72
Patient 4	1,501,130	453	9067.53	8965.74	6690	119267	42	0.14	99.86	99.84	99.83	99.8
Patient 2	1,710,539	517	11420.22	10814.68	8203	91027	41	0.14	99.85	99.84	99.83	99.72

## References

1. New York City COVID-19 Cases Caused by SARS-CoV-2 Variants Report (3.23 .2021). 2021;0:2021.
2. Ogawa J, Zhu W, Tonnu N, et al. The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner. *bioRxiv*. 2020;90033(4). doi:10.1101/2020.07.21.214932
3. Hatmal MM, Alshaer W, Al-Hatamleh MAI, et al. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. *Cells*. 2020;9(12). doi:10.3390/cells9122638
4. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol*. 2021;614. doi:10.1038/s41579-021-00573-0
5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020;181(2):281-292.e6. doi:10.1016/j.cell.2020.02.058
6. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature*. 2020;586(7830):594-599. doi:10.1038/s41586-020-2814-7
7. Mullen JL, Tseung G, Latif AA, et al. Center for Viral Systems Biology outbreak.info. Published 2020. <https://outbreak.info/>
8. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. *bioRxiv*. 2016;(212):6-8.
9. Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant Background. :0-2.
10. Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *Clin Infect Dis*. 2021;6(2):106192. doi:10.1093/cid/ciab411
11. Bartsch SM, O'Shea KJ, Ferguson MC, et al. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. *Am J Prev Med*. 2020;59(4):493-503. doi:10.1016/j.amepre.2020.06.011
12. Paden CR, Tao Y, Queen K, et al. Rapid, Sensitive, Full-Genome Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2020;26(10):2401-2405. doi:10.3201/eid2610.201800
13. Cingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. *Fly (Austin)*. 2012;6(2):80-92. doi:10.1101/2021.03.09.21252822
14. Mercatelli D, Triboli L, Fornasari E, Ray F, Giorgi FM. Coronapp: A web application to annotate and monitor SARS-CoV-2 mutations. *J Med Virol*. 2021;93(5):3238-3245. doi:10.1002/jmv.26678

15. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. *Glob Challenges*. 2017;1(1):33-46. doi:10.1002/gch2.1018
16. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol*. 2020;5(11):1403-1407. doi:10.1038/s41564-020-0770-5
17. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol Biol Evol*. 2013;30(4):772-780. doi:10.1093/molbev/mst010
18. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast Bootstrap Approximation. *Molecular biology and evolution*. *Mol Biol Evol*. 2018;35(2):518-522. doi:10.5281/zenodo.854445
19. Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol*. 2020;37(5):1530-1534. doi:10.1093/molbev/msaa015